Canada's KP Tissue Q3 revenue rises on higher sales volumes

KP Tissue

Wed 12:10

Overview
Canada tissue maker's Q3 revenue rose 5.1% yr/yr on higher sales volumes and pricing
Adjusted EBITDA for Q3 rose 9.1% yr/yr
Q3 net income more than doubled from a year ago

Outlook
Company expects Q4 2026 Adjusted EBITDA to be slightly below Q3, but above Q4 2025
Company expects escalating input costs and inflationary pressure in coming quarters
Company anticipates delay in new TAD facility, not commencing operations in 2028

Result Drivers
CONSUMER SEGMENT GROWTH - Higher sales volumes in the Consumer segment and favourable selling prices in the U.S. Consumer business drove revenue gains
COST PRESSURES - Increased manufacturing overhead, higher freight and warehousing costs, and foreign exchange impacts raised costs, partially offset by lower pulp costs
BRAND INVESTMENT - Continued investment in brands contributed to sales growth in both Canada and the U.S.

Company press release: ID:nNFC46ZCZz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
C$589.66 mln
C$574.90 mln (2 Analysts)
Q3 Net Income
 
C$27.71 mln
 
Q3 Adjusted EBITDA
 
C$93.50 mln
 
Q3 Operating Income
 
C$59.81 mln
 
Q3 Pretax Profit
 
C$41.81 mln
 

Reuters Recommended Reads
Nov 10 - Canada's CCL Industries Q3 sales rise driven by Avery, CCL, Innovia
Nov 10 - Canada's Pet Valu Q3 revenue beats estimates on retail sales; lifts outlook
Nov 9 - Hain Celestial Q1 sales misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)